Therapeutic approach to multiple sclerosis by novel oral drugs

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 5, Issue 1, 2011, Pages 66-80

  Jadidi Niaragh, Farhad ^a   Mirshafiey, Abbas ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cladribine; Experimental autoimmune encephalomyelitis; Fingolimod; FTY720; Fumaric acid; Laquinimod; Multiple sclerosis; Teriflunomide; Triptolide

Indexed keywords

ANTIINFLAMMATORY AGENT; BETA INTERFERON; BETA1A INTERFERON; BG 00012; CLADRIBINE; CYCLOPHOSPHAMIDE; FINGOLIMOD; FUMARIC ACID; FUMARIC ACID DERIVATIVE; FUMARIC ACID DIMETHYL ESTER; FUMARIC ACID METHYL ESTER; GLATIRAMER; IMMUNOSUPPRESSIVE AGENT; INTERFERON BETA SERINE; LAQUINIMOD; MITOXANTRONE; NATALIZUMAB; PLACEBO; ROQUINIMEX; TERIFLUNOMIDE; TRIPTOLIDE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ADD ON THERAPY; ALLERGIC ENCEPHALITIS; ALLERGIC ENCEPHALOMYELITIS; ALOPECIA; ALZHEIMER DISEASE; ANKLE EDEMA; ARTHRALGIA; ASTHMA; ATRIOVENTRICULAR BLOCK; AUTOIMMUNE DISEASE; BRADYCARDIA; BUDD CHIARI SYNDROME; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC INFLAMMATION; CROHN DISEASE; DEATH; DIARRHEA; DISABILITY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG HALF LIFE; DRUG STRUCTURE; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FLUSHING; HEADACHE; HEART INFARCTION; HERPES VIRUS INFECTION; HERPES ZOSTER; HOT FLUSH; HUMAN; HYPERTENSION; HYPOPHYSIS ADENOMA; INFLUENZA; LARYNX PAIN; LEPROSY; LEUKOCYTE; LIVER DYSFUNCTION; LYMPHOCYTOPENIA; MULTIPLE SCLEROSIS; NAUSEA; NEPHRITIS; NEUTROPENIA; NONHUMAN; PARESTHESIA; PARKINSON DISEASE; PATENT; PERICARDITIS; PLEURISY; PRIORITY JOURNAL; RETINA MACULA EDEMA; REVIEW; RHABDOMYOLYSIS; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; SKIN CANCER; SORE THROAT; SYSTEMIC LUPUS ERYTHEMATOSUS; TRIGEMINUS NEURALGIA;

ADMINISTRATION, ORAL; CLADRIBINE; CROTONIC ACIDS; DITERPENES; EPOXY COMPOUNDS; FUMARATES; HUMANS; MULTIPLE SCLEROSIS; PATENTS AS TOPIC; PHENANTHRENES; PROPYLENE GLYCOLS; QUINOLONES; SPHINGOSINE; TOLUIDINES;

EID: 79551628910     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221311794474900     Document Type: Review

References (152)

1. Hemmer B, Frohman E, Hartung HP, Stuve O. Central nervous system infections - A potential complication of systemic immunotherapy. Curr Opin Neurol 2006; 19(3): 271-6.
2. Muller DM, Pender MP, Greer JM. Chemokines and chemokine receptors: Potential therapeutic targets in multiple sclerosis. Curr Drug Targets Inflamm Allergy 2004; 3(3): 279-90.
3. Mirshafiey A. Novel promising therapeutic agents in multiple sclerosis. Recent Pat Inflamm Allergy Drug Discov 2007; 1(3): 218-24.
4. Menge T, Weber MS, Hemmer B, Kieseier BC, von Büdingen HC, Warnke C, et al. Disease-modifying agents for multiple sclerosis: Recent advances and future prospects. Drugs 2008; 68(17): 2445-68.
5. Mirshafiey A, Matsuo H, Nakane S, Rehm BH, Koh CS, Miyoshi S. Novel immunosuppressive therapy by M2000 in experimental multiple sclerosis. Immunopharmacol Immunotoxicol 2005; 27(2): 255-65.
6. Nicot A. Gender and sex hormones in multiple sclerosis pathology and therapy. Front Biosci 2009; 14: 4477-515.
7. Bruck W. The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage. J Neurol 2005; 2525: 3-9.
8. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000; 28: 343(13): 938-52.
9. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005; 23; 683-747.
10. Leray E, Yaouanq J, Le PE, Coustans M, Laplaud D, Oger J, et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain 2010; 133(Pt 7): 1900-13.
11. Hutter CD, Laing P. Multiple sclerosis: Sunlight, diet, immunology and aetiology. Med Hypotheses 1996; 46(2): 67-74.
12. Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr 2002; 21(6): 495-505.
13. Sadovnick AD, Dyment D, Ebers GC. Genetic epidemiology of multiple sclerosis. Epidemiol Rev 1997; 19 (1): 99-106.
14. Mirshafiey A, Mohsenzadegan M. Immunotoxicological effects of reactive oxygen species in multiple sclerosis. J CN Clin Med 2008; 3(7): 405-11.
15. Frohman EM, Racke MK, Raine CS. Multiple sclerosis--the plaque and its pathogenesis. N Engl J Med 2006; 354(9): 942-55.
16. McFarland HF, Martin R. Multiple sclerosis: A complicated picture of autoimmunity. Nat Immunol 2007; 8(9): 913-9.
17. Babbe H, Roers A, Waisman A, Lassmann H, Goebels N, Hohlfeld R, et al. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 2000; 192(3): 393-404.
18. Jacobsen M, Cepok S, Quak E, Gaber R, Ziegler A, Happel M, et al. Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patients. Brain 2002; 125(Pt 3): 538-50.
19. Lafaille JJ, Keere FV, Hsu AL, Baron JL, Haas W, Raine CS, et al. Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease. J Exp Med 1997; 186(2): 307-12.
20. Bettelli E, Oukka M, Kuchroo VK. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007; 8(4): 345-50.
21. Thakker P, Leach MW, Kuang W, Benoit SE, Leonard JP, Marusic S. IL-23 is critical in the induction but not in the effector phase of experimental autoimmune encephalomyelitis. J Immunol 2007; 178(4): 2589-98.
22. Owens T. The enigma of multiple sclerosis: Inflammation and neurodegeneration cause heterogeneous dysfunction and damage. Curr Opin Neurol 2003; 16(3): 259-65.
23. Peterson LK, Fujinami RS. Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis. J Neuroimmunol 2007; 184(1-2): 37-44.
24. Constam DB, Philipp J, Malipiero UV, ten DP, Schachner M, Fontana A. Differential expression of transforming growth factorbeta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia. J Immunol 1992; 148(5): 1404-10.
25. Huan J, Culbertson N, Spencer L, Bartholomew R, Burrows GG, Chou YK, et al. Decreased FOXP3 levels in multiple sclerosis patients. J Neurosci Res 2005; 81(1): 45-52.
26. Barnstein BO, Li G, Wang Z, Kennedy S, Chalfant C, Nakajima H, et al. Stat5 expression is required for IgE-mediated mast cell function. J Immunol 2006; 177(5): 3421-6.
27. Mirshafiey A, Aghily B, Namaki S, Razavi A, Ghazavi A, Ekhtiari P, et al. Therapeutic approach by Aloe vera in experimental model of multiple sclerosis. Immunopharmacol Immunotoxicol 2010; 32(3): 410-5.
28. Mosayebi G, Haghmorad D, Namaki S, Ghazavi A, Ekhtiari P, Mirshafiey A. Therapeutic Effect of EDTA in experimental model of multiple sclerosis. Immunopharmacol Immunotoxicol 2010; [Epub ahead of schedule].
29. Gasperini C, Ruggieri S. New oral drugs for multiple sclerosis. Neurol Sci 2009; 30 (Suppl 2): S179-S83.
30. Gasperini C, Cefaro LA, Borriello G, Tosto G, Prosperini L, Pozzilli C. Emerging oral drugs for multiple sclerosis. Expert Opin Emerg Drugs 2008; 13(3): 465-77.
31. Kieseier BC, Wiendl H. Oral disease-modifying treatments for multiple sclerosis: The story so far. CNS Drugs 2007; 21(6): 483-502.
32. Mirshafiey A. Novel promising therapeutic agents in multiple sclerosis. Recent Pat Inflamm Allergy Drug Discov 2007; 1(3): 218-4.
33. Sanna MG, Liao J, Jo E, Razavi A, Ghazavi A, Ekhtiari P, et al. Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem 2004; 279(14): 13839-48.
34. Foster CA, Howard LM, Schweitzer A, Persohn E, Hiestand PC, Balatoni B, et al. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther 2007; 323(2): 469-75.
35. Kimura A, Ohmori T, Ohkawa R, Madoiwa S, Mimuro J, Murakami T, et al. Essential roles of sphingosine 1-phosphate/S1P1 receptor axis in the migration of neural stem cells toward a site of spinal cord injury. Stem Cells 2007; 25(1): 115-24.
36. Coelho RP, Payne SG, Bittman R, Spiegel S, Sato-Bigbee C. The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors. J Pharmacol Exp Ther 2007; 323(2): 626-35.
37. Miron VE, Jung CG, Kim HJ, Kennedy TE, Soliven B, Antel JP. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol 2008; 63(1): 61-71.
38. Balatoni B, Storch MK, Swoboda EM, Schönborn V, Koziel A, Lambrou GN, et al. FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. Brain Res Bull 2007; 74(5): 307-16.
39. Fujino M, Funeshima N, Kitazawa Y, Kimura H, Amemiya H, Suzuki S, et al. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther 2003; 305(1): 70-7.
40. Rausch M, Hiestand P, Foster CA, Baumann DR, Cannet C, Rudin M. Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: Clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. J Magn Reson Imaging 2004; 20(1): 16-24.
41. Rammohan KW, Shoemaker J. Emerging multiple sclerosis oral therapies. Neurology 2010; 74 (Suppl 1): S47-S53.
42. Brinkmann V. FTY720 (fingolimod) in Multiple Sclerosis: Therapeutic effects in the immune and the central nervous system. Br J Pharmacol 2009; 158(5): 1173-82.
43. Kappos L, Antel J, Comi G. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006; 355(11): 1124-40.
44. O'Connor PW, Li D, Freedman MS, Bar-Or A, Rice GP, Confavreux C, et al. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006; 66(6): 894-900.
45. Comi G, O'Connor P, Montalban X, Antel J, Radue EW, Karlsson G, et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler 2010; 16(2): 197-207.
46. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362(5): 387-401.
47. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362(5): 402-15.
48. Cee, V.J., Frohn, M.J., Lanman, B. A., Neira, S. C., Reed, A. B.,Sham, K.K.C. Use of S1P1 agonist in treatment of autoimmune diseases. US7678820 (2010).
49. Kudou, S., Kuriyama, K., Yasue, T. Effective use method of medicaments and method of preventing expression of side effect. US7781617 (2010).
50. Tsubuki, T., Kobayashi, K., Komatsu, H. Process for producing 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl]-1,3-propanediol hydrochloride and hydrates thereof, and intermediates in the production thereof. US7795472 (2010).
51. De Luca, G., Ythier, A., Munafo, A., Lopez-Bresnahan, M. Cladribine regimen for treating multiple sclerosis. US0081163 (2009).
52. Robins, M. J., Janeba, Z., Francom, P. Method for the pre-paration of 2-halo-2́-deoxyadenosine compounds for 2́-deoxyguanosine. US20070032645 (2007).
53. Bodor, N.S., Dandiker, Y. Oral formulation of cladribine. US20070197468 (2007).
54. Beutler, E. Use of substituted adenine derivatives for treating multiple sclerosis. US5506214 (1996).
55. Winter, A. Multiple sclerosis treatment. US5716946 (1998).
56. Schultz, T. W., Naeff, R. Cyclodextrin cladribine formulation. US6194395 (2001).
57. Jung, M.J., Wickramaratne, M., Hepperle, M. Triptolide derivatives useful in the treatment of autoimmune diseases. US5972998 (1999) & US6004999 (1999).
58. Wang, S., Liotta, D. C., Snyder, J. P., Venkatesan, H. Triptolide analogs for the treatment of autoimmune and inflammatory disorders. US20030027806 (2003) &US6777441 (2004).
59. Venkatesan, H., Snyder, J. P., Liotta, D. C. Triptolide analogs for the treatment of autoimmune and inflammatory disorders. US20060040907 (2006).
60. Venkatesan, H., Snyder, J. P., Liotta, D. C., Wang, S. Triptolide analogs for the treatment of autoimmune and inflammatory disorders. US7557139 (2009).
61. Wang, S., Liotta, D. C., Snyder, J. P., Venkatesan, H. Triptolide analogs for the treatment of autoimmune and inflammatory disorders. US20090234000 (2009).
62. Patashnik, S., Licht, D., Gilbert, A. Stable laquinimod preparations. US20070293537 (2007).
63. Wettstein, J. Use of (Z) -2-cyano-3-hydroxy-but-2-enoic acid-(4' -trifluoromethylphenyl)-amide for treating multiple sclerosis. US20020177623 (2002) & US20030223960 (2003) & US6794410 (2004).
64. Joshi, R. K., Strebel, H. P. Use of fumaric acid derivatives. US6436992 (2002).
65. Joshi, R. K., Strebel, H.-P. Fumaric acid amides. US20040038889 (2004) & US20060205659 (2006) & US7157423 (2007) & US7432240 (2008).
66. Joshi, R. K., Strebel, H.-P. Dimethyl fumarate for the treatment of multiple sclerosis. US7320999 (2008).
67. Nilsson, H., Andersen, J. E. T., Mueller, B. W. Novel salts of fumaric acid monoalkylesters and their pharmaceutical use. US20080227847 (2008).
68. Linker RA, Kieseier BC, Gold R. Identification and development of new therapeutics for multiple sclerosis. Trends Pharmacol Sci 2008; 29(11): 558-65.
69. Kopadze T, Dobert M, Leussink VI, Dehmel T, Kieseier BC. Cladribine impedes in vitro migration of mononuclear cells: A possible implication for treating multiple sclerosis. Eur J Neurol 2009; 16(3): 409-12.
70. Liliemark J. The clinical pharmacokinetics of cladribine. Clin Pharmacokinet 1997; 32(2): 120-31.
71. Beutler E, Sipe J, Romine J, McMillan R, Zyroff J, Koziol J. Treatment of multiple sclerosis and other autoimmune diseases with cladribine. Semin Hematol 1996; 33(1 Suppl 1): 45-52.
72. Schirmer M, Mur E, Pfeiffer KP, Thaler J, Konwalinka G. The safety profile of low-dose cladribine in refractory rheumatoid arthritis. A pilot trial. Scand J Rheumatol 1997; 26(5): 376-9.
73. Sipe JC. Cladribine for multiple sclerosis: Review and current status. Expert Rev Neurother 2005; 5(6): 721-7.
74. Beutler E, Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci USA 1996; 20; 93(4): 1716-20.
75. Romine JS, Sipe JC, Koziol JA, Zyroff J, Beutler E. A doubleblind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Physicians 1999; 111(1): 35-44.
76. Rice GP, Filippi M, Comi G. Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 2000; 54(5): 1145-55.
77. Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010; 362(5): 416-26.
78. Hartung HP, Aktas O, Kieseier B, Comi GGC. Development of oral cladribine for the treatment of multiple sclerosis. J Neurol 2010; 257(2): 163-70.
79. Qiu D, Kao PN. Immunosuppressive and anti-inflammatory mechanisms of triptolide, the principal active diterpenoid from the Chinese medicinal herb Tripterygium wilfordii Hook. f. Drugs R D 2003; 4(1): 1-18.
80. Pan XD, Chen XC. Advances in the study of immunopharmacological effects and mechanisms of extracts of Tripterygium wilfordii Hook. f. in neuroimmunologic disorders. Yao Xue Xue Bao 2008; 43(12): 1179-85.
81. Fan HC, Ren XR, Yu JZ, Guo MF, Ji N, Sun YS, et al. Suppression of murine EAE by triptolide is related to downregulation of INFgamma and upregulation of IL-10 secretion in splenic lymphocytes. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2009; 25(3): 222-5.
82. van EW. Protective and therapeutic effect of triptolide in EAE explained by induction of major stress protein HSP70. J Neuroimmunol 2009; 217(1-2): 10-1.
83. Kizelsztein P, Komarnytsky S, Raskin I. Oral administration of triptolide ameliorates the clinical signs of experimental autoimmune encephalomyelitis (EAE) by induction of HSP70 and stabilization of NF-kappaB/IkappaBalpha transcriptional complex. J Neuroimmunol 2009; 217(1-2): 28-37.
84. Fu YF, Zhu YN, Ni J, Zhong XG, Tang W, Zhou R, et al. (5R)-5- hydroxytriptolide (LLDT-8), a novel triptolide derivative, prevents experimental autoimmune encephalomyelitis via inhibiting T cell activation. J Neuroimmunol 2006; 175(1-2): 142-51.
85. Wang Y, Mei Y, Feng D, Xu L. Triptolide modulates T-cell inflammatory responses and ameliorates experimental autoimmune encephalomyelitis. J Neurosci Res 2008; 86(11): 2441-9.
86. Qiu D, Zhao G, Aoki Y, Shi L, Uyei A, Nazarian S, et al. Immunosuppressant PG490 (triptolide) inhibits T-cell interleukin-2 expression at the level of purine-box/nuclear factor of activated Tcells and NF-kappaB transcriptional activation. J Biol Chem 1999; 274(19): 13443-50.
87. Yang SX, Gao HL, Xie SS, Zhang WR, Long ZZ. Immunosuppression of triptolide and its effect on skin allograft survival. Int J Immunopharmacol 1992; 14(6): 963-9.
88. Zhao G, Vaszar LT, Qiu D, Shi L, Kao PN. Anti-inflammatory effects of triptolide in human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 2000; 279(5): L958-L966.
89. Chan MA, Kohlmeier JE, Branden M, Jung M, Benedict SH. Triptolide is more effective in preventing T cell proliferation and interferon-gamma production than is FK506. Phytother Res 1999; 13(6): 464-7.
90. Lin N, Sato T, Ito A. Triptolide, a novel diterpenoid triepoxide from Tripterygium wilfordii Hook. f., suppresses the production and gene expression of pro-matrix metalloproteinases 1 and 3 and augments those of tissue inhibitors of metalloproteinases 1 and 2 in human synovial fibroblasts. Arthritis Rheum 200; 44(9): 2193-200.
91. Krishna G, Liu K, Shigemitsu H, Gao M, Raffin TA, Rosen GD. PG490-88, a derivative of triptolide, blocks bleomycin-induced lung fibrosis. Am J Pathol 200; 158(3): 997-1004.
92. Yang SX, Xie SS, Gag HL, Ma DL, Long ZZ. Triptolide suppresses T-lymphocyte proliferation by inhibiting interleukin-2 receptor expression, but spares interleukin-2 production and mRNA expression. Int J Immunopharmacol 1994; 16(11): 895-904.
93. Maekawa K, Yoshikawa N, Du J, Nishida S, Kitasato H, Okamoto K, et al. The molecular mechanism of inhibition of interleukin-1beta-induced cyclooxygenase-2 expression in human synovial cells by Tripterygium wilfordii Hook F extract. Inflamm Res 1999; 48(11): 575-81.
94. Chang DM, Kuo SY, Lai JH, Chang ML. Effects of anti-rheumatic herbal medicines on cellular adhesion molecules. Ann Rheum Dis 1999; 58(6): 366-71.
95. Tao X, Schulze-Koops H, Ma L, Cai J, Mao Y, Lipsky PE. Effects of Tripterygium wilfordii Hook F extracts on induction of cyclooxygenase 2 activity and prostaglandin E2 production. Arthritis Rheum 1998; 41(1): 130-8.
96. Tao X, Davis LS, Hashimoto K, Lipsky PE. The Chinese herbal remedy, T2, inhibits mitogen-induced cytokine gene transcription by T cells, but not initial signal transduction. J Pharmacol Exp Ther 1996; 276(1): 316-25.
97. Yang Y, Liu ZH, Tolosa E, Yang JW, Li LS. Triptolide induces apoptotic death of T lymphocyte. Immunopharmacology 1998; 40(2): 139-49.
98. Matta R, Wang X, Ge H, Ray W, Nelin LD, Liu Y. Triptolide induces anti-inflammatory cellular responses. Am J Transl Res 2009; 1(3): 267-82.
99. Zha QL, He YT, Yu JP. Correlations between diagnostic information and therapeutic efficacy in rheumatoid arthritis analyzed with decision tree model. Zhongguo Zhong Xi Yi Jie He Za Zhi 2006; 26(10): 871-6.
100. Wu SX, Guo NR. Clinical observation on effect of triptolide tablet in treating patients with psoriasis vulgaris. Chin J Integr Med 2005; 11(2): 147-8.
101. Song HX, Gong J, Chen W. Effect of triptolide on urinary monocyte chemottractant protein-1 in patients with diabetic nephropathy. Zhongguo Zhong Xi Yi Jie He Za Zhi 2005; 25(5): 416-18.
102. Wang XH, Zhang ZY. Effect of Tripterygium polyglucoside on Tlymphocyte subsets and serum interleukin-5 level in asthma patients. Zhongguo Zhong Xi Yi Jie He Za Zhi 2001; 21(1): 25-7.
103. Noseworthy JH, Wolinsky JS, Lublin FD, Whitaker JN, Linde A, Gjorstrup P, et al. Linomide in relapsing and secondary progressive MS: Part I: Trial design and clinical results. Neurology 2000; 54(9): 1726-33.
104. Yang JS, Xu LY, Xiao BG, Hedlund G, Link H. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J Neuroimmunol 2004; 156(1-2): 3-9.
105. Brunmark C, Runstrom A, Ohlsson L, Sparre B, Brodin T, Aström M, et al. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J Neuroimmunol 2002; 130(1-2): 163-72.
106. Preiningerova J. Oral laquinimod therapy in relapsing multiple sclerosis. Expert Opin Investig Drugs 2009; 18(7): 985-9.
107. Keegan BM, Weinshenker BG. Laquinimod, a new oral drug for multiple sclerosis. Lancet 2008; 371(9630): 2059-60.
108. Runstrom A, Leanderson T, Ohlsson L, Axelsson B. Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-beta k.o. and wild type mice. J Neuroimmunol 2006; 173(1-2): 69-78.
109. Achiron A. Laquinimod reduced level of IL-17 in cultured splenocytes form treated MOG induced experimental autoimmuneencephalomyelitis and in cultured PBMCs from healthy human donors. Neurology 2008; 70(1): A374.
110. Achiron A. Laquinimod induced downregulation of MHC class II gene expression in cultured peripheral blood blood cells of untreated patients with multiple sclerosis. Neurology 2008; 70(1): A376.
111. Gurevich M, Gritzman T, Orbach R, Tuller T, Feldman A, Achiron A. Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: In vitro High-throughput gene expression study. J Neuroimmunol 2010; 221(1-2): 87-94.
112. Tselis A. Laquinimod, a new oral autoimmune modulator for the treatment of relapsing-remitting multiple sclerosis. Curr Opin Investig Drugs 2010; 11(5): 577-85.
113. Polman C, Barkhof F, Sandndberg-Wollheim M, Linde A, Nordle O, Nederman T. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 2005; 64(6): 987-91.
114. Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T, Boiko A, et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: A multicentre, randomised, double-blind, placebo-controlled phase IIb study. The Lancet 2008; 371(9630): 2085-92.
115. Comi G, Abramsky O, Arbizu T. Long-term open extension of oral laquinimod in patients with relapsing multiple sclerosis shows favourable safety and sustained low relapse rate and MRI activity. Presented at European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting 2009.
116. Sorensen PS, Vollmer T, Arnold DL. Benefit-to-risk ratio comparison of oral laquinimod and interferon beta-1a im in relapsing-remitting multiple sclerosis: Study design of the 2-year phase III BRAVO trial. Presented at European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting 2009.
117. Comi G, Jeffery D, Kappos L. Baseline demographics of a placebocontrolled, double-blind, randomised study of oral laquinimod 0.6 mg in treating relapsing-remitting multiple sclerosis: The ALLEGRO study. Presented at European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting 2009.
118. Kieseier BC, Wiendl H, Hartung HP, Stuve O. The future of multiple sclerosis therapy. Pharmacol Res 2009; 60(4): 207-11.
119. Korn T, Toyka K, Hartung HP, Jung S. Suppression of experimental autoimmune neuritis by leflunomide. Brain 2001; 124(9): 1791-802.
120. Korn T, Magnus T, Toyka K, Jung S. Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide - Mechanisms independent of pyrimidine depletion. J Leukoc Biol 2004; 76(5): 950-60.
121. Williamson RA, Yea CM, Robson PA, Curnock AP, Gadher S, Hambleton AB, et al. Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound. J Biol Chem 1995; 270(38): 22467-72.
122. Merrill JE, Hanak S, Pu SF, Liang J, Dang C, Iglesias-Bregna D, et al. Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the dark agouti rat model of experimental autoimmune encephalomyelitis. J Neurol 2009; 256(1): 89-103.
123. Tallantyre E, Evangelou N, Constantinescu CS. Spotlight on teriflunomide. Int MS J 2008; 15(2): 62-8.
124. Warnke C, Zu MHG, Hartung HP, Stuve O, Kieseier BC. Review of teriflunomide and its potential in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat 2009; 5: 333-40.
125. Schweckendiek W. Treatment of psoriasis vulgaris. Med Monatsschr 1959; 13(2): 103-4.
126. Moharregh-Khiabani D, Linker RA, Gold R, Stangel M. Fumaric acid and its esters: An emerging treatment for multiple sclerosis. Curr Neuropharmacol 2009; 7(1): 60-4.
127. Litjens NHR, Burggraaf J, Van Strijen E, van Gulpen C, Mattie H, Schoemaker RC, et al. Pharmacokinetics of oral fumarates in healthy subjects. Br J Clin Pharmacol 2004; 58(4): 429-32.
128. Mrowietz U, Christophers E, Altmeyer P. Treatment of psoriasis with fumaric acid esters: Results of a prospective multicentre study. Br J Dermatol 1998; 138(3): 456-60.
129. Nibbering PH, Thio B, Zomerdijk TPL, Bezemer AC, Beijersbergen RL, Van Furth R. Effects of monomethylfumarate on human granulocytes. J Invest Dermatol 1993; 101(1): 37-42.
130. Werdenberg D, Joshi R, Wolffram S, Merkle HP, Langguth P. Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid esters. Biopharm Drug Dispos 2003; 24(6): 259-73.
131. De Jong R, Bezemer AC, Zomerdijk TPL, Van Pouw-Kraan TD, Ottenhoff THM, Nibbering PH. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur J Immunol 1996; 26(9): 2067-74.
132. Asadullah K, Schmid H, Friedrich M, Randow F, Volk HD, Sterry W, et al. Influence of monomethylfumarate on monocytic cytokine formation - Explanation for adverse and therapeutic effects in psoriasis? Arch Dermatol Res 1997; 289(11): 623-30.
133. Ockenfels HM, Schultewolter T, Ockenfels G, Funk R, Goos M. The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. Br J Dermatol 1998; 139(3): 390-95.
134. Sebok B, Bonnekoh B, Vetter R, Schneider I, Gollnick H, Mahrle G. The antipsoriatic dimethyl-fumarate suppresses interferongamma-induced ICAM-1 and HLA-DR expression on hyperproliferative keratinocytes. Quantification by a culture platedirected APAAP-ELISA technique. Eur J Dermatol 1998; 8(1): 29-32.
135. Vandermeeren M, Janssens S, Borgers M, Geysen J. Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells. Biochem Biophys Res Commun 1997; 234(1): 19-23.
136. Treumer F, Zhu K, Glãser R, Mrowietz U. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol 2003; 121(6): 1383-8.
137. Zhu K, Mrowietz U. Inhibition of dendritic cell differentiation by fumaric acid esters. J Invest Dermatol 2001; 116(2): 203-8.
138. Litjens NHR, Rademaker M, Ravensbergen B, Rea D, van der Plas MJ, Thio B, et al. Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses. Eur J Immunol 2004; 34(2): 565-75.
139. Lee DH, Linker RA, Gold R. Spotlight on fumarates. Int MS J 2008; 15(1): 12-8.
140. Loewe R, Holnthoner W, Groger M, Pillinger M, Gruber F, Mechtcheriakova D, et al. Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappaB/p65 in human endothelial cells. J Immunol 2002; 168(9): 4781-7.
141. Stoof TJ, Flier J, Sampat S, Nieboer C, Tensen CP, Boorsma DM. The antipsoriatic drug dimethylfumarate strongly suppresses chemokine production in human keratinocytes and peripheral blood mononuclear cells. Br J Dermatol 2001; 144(6): 1114-20.
142. Hayden MS, West AP, Ghosh S. NF-kappaB and the immune response. Oncogene 2006; 25(51): 6758-80.
143. van Muiswinkel FL, Kuiperij HB. The Nrf2-ARE signalling pathway: Promising drug target to combat oxidative stress in neurodegenerative disorders. Curr Drug Targets CNS Neurol Disord 2005; 4(3): 267-81.
144. Wierinckx A, Breve J, Mercier D, Schultzberg M, Drukarch B, Van Dam AM. Detoxication enzyme inducers modify cytokine production in rat mixed glial cells. J Neuroimmunol 2005; 166(1-2): 132-43.
145. SantaCruz KS, Yazlovitskaya E, Collins J, Johnson J, DeCarli C. Regional NAD(P)H: Quinone oxidoreductase activity in Alzheimer's disease. Neurobiol Aging 2004; 25(1): 63-9.
146. van Muiswinkel FL, DeVos R, Bol J, Andringa G, Jansen S, Ross D, et al. Expression of NAD(P)H: Quinone oxidoreductase in the normal and Parkinsonian substantia nigra. Neurobiol Aging 2004; 25(9): 1253-62.
147. Lukashev M. Activation of Nrf2 and modulation of disease by BG00012 (dimethylfumarate) suggest a dual cytoprotective and anti-inflammatory mechanism of action. Neurology 2008; (Suppl 1): A27.
148. Schilling S, Goelz S, Linker R, Luehder F, Gold R. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol 2006; 145(1): 101-7.
149. Schmidt MM, Dringen R. Fumaric acid diesters deprive cultured primary astrocytes rapidly of glutathione. Neurochem Int 2010; 57(4): 460-7.
150. Thiessen A, Schmidt MM, Dringen R. Fumaric acid dialkyl esters deprive cultured rat oligodendroglial cells of glutathione and upregulate the expression of heme oxygenase 1. Neurosci Lett 2010; 475(1): 56-60.
151. Schimrigk S, Brune N, Hellwig K, Lukas C, Bellenberg B, Rieks M, et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: An open-label, baseline-controlled pilot study. Eur J Neurol 2006; 13(6): 604-10.
152. Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: A multicentre, randomised, double-blind, placebo-controlled phase IIb study. J Lancet 2008; 372(9648): 1463-72.